July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Ranibizumab and Aflibercept: Baseline and 12-month visual outcomes of patients at a large tertiary ophthalmic hospital
Author Affiliations & Notes
  • Siegfried K Wagner
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Katrin Fasler
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Farid Afshar
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Reena Chopra
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Karsten Ulrich Kortuem
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
    University Eye Hospital, Munich, Germany
  • Nikolas Pontikos
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Thushanthi Ramakrishnan
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Ella Preston
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Praveen Patel
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Adnan Tufail
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Konstantinos Balaskas
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Pearse Andrew Keane
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships   Siegfried Wagner, None; Katrin Fasler, Alfred Vogt Stipendium (F), Schweizerischer Fonds zur Verhütung und Bekämpfung der Blindheit (F); Farid Afshar, None; Reena Chopra, None; Karsten Kortuem, Allergan (R), Bayer (R), Google (C), Haag-Streit (R), Heidelberg (R), Novartis (R), Topcon (R), Zeiss (R); Nikolas Pontikos, None; Thushanthi Ramakrishnan, None; Ella Preston, Bayer (R), City, University of London (E); Praveen Patel, Bayer (C), Genentech (C), Heidelberg Inc (F), Merk Inc (C), Novartis (C), Roche UK (C), SalutarisMD (R), Thombogenics NV (C), Thrombogenics NV (F), Topcon Inc (F); Adnan Tufail, Allergan (F), Astellas (C), Bayer (F), Genentech (C), Heidelberg Engineering (F), Kanghong (C), Novartis (F), Novartis (C), Roche (F), Thrombogenics NV (C); Konstantinos Balaskas, Bayer (R), Heidelberg (R), Novartis (C), Novartis (R), Topcon (R); Pearse Keane, Allergan (R), Bayer (R), Google (C), Haag-Streit (R), Heidelberg Engineering (R), Novartis (R), Topcon (R), Zeiss (R)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 815. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Siegfried K Wagner, Katrin Fasler, Farid Afshar, Reena Chopra, Karsten Ulrich Kortuem, Nikolas Pontikos, Thushanthi Ramakrishnan, Ella Preston, Praveen Patel, Adnan Tufail, Konstantinos Balaskas, Pearse Andrew Keane; Ranibizumab and Aflibercept: Baseline and 12-month visual outcomes of patients at a large tertiary ophthalmic hospital. Invest. Ophthalmol. Vis. Sci. 2018;59(9):815. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : When aflibercept received FDA approval in 2011 for neovascular age-related macular degeneration (nAMD), many patients were commenced with this treatment on a fixed dosing in the first year (as per the posology), followed by a treat and extend regimen. Previously, ranibizumab was the only licensed drug to treat this condition, the most common regimen being pro re nata after 3 loading injections (each a month apart). In this retrospective study, we compare baseline and 12 month visual acuity outcomes for the respective agents.

Methods : The Moorfields Eye Hospital Electronic Medical Record system was queried for patients who had received intravitreal anti-VEGF injections for nAMD for 12 months or more between 2008 and 2017. This was stratified into eyes having received either only ranibizumab or only aflibercept throughout the course. Baseline and 12 month visual acuity was recorded in ETDRS letters. Statistical analysis was carried out using SPSS version 23.

Results : A total of 989 and 1425 eyes had received treatment for 12 months or more with ranibizumab and aflibercept respectively. Mean year of first presentation for patients under ranibizumab was 2010 and for aflibercept 2014 while age distribution was similar (mean 79 years for both groups). Mean (±SD) baseline visual acuity for the eyes receiving ranibizumab was 54.89 (±15) letters with a gain of 2.55 letters after 12 months. Mean baseline visual acuity for the eyes receiving aflibercept was 57.05 (±16) letters with a gain of 5.93 letters at 12 months. Mean number of injections during the first year was 6 (±2) for ranibizumab and 8 (±1) for aflibercept.

Conclusions : Although baseline visual acuity was lower for the patients who received ranibizumab, the mean letter gain after 12 months was greater for the patients receiving aflibercept. This may be related to the treatment regimen i.e. pro re nata versus fixed dosing resulting in more injections in the aflibercept group in addition to differences in the drug. Further data and analysis is required to determine any longer-term differences in visual acuity taking into account posology and baseline characteristics.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×